In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 111 to 120 of 376

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]	Technology appraisal guidance	19 June 2025
Efgartigimod for treating generalised myasthenia gravis [ID4003]	Technology appraisal guidance	TBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409	Technology appraisal guidance	TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	25 June 2025
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	23 July 2025
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma	Interventional procedures guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]	Technology appraisal guidance	24 July 2025
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]	Technology appraisal guidance	TBC

Results per page

10
25
50
All